In a post hoc analysis of the SURPASS-CVOT randomized clinical trial, researchers found that tirzepatide was associated with fewer cardiorenal events than dulaglutide in high-risk type 2 diabetes.
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
A double-blind, placebo-controlled cross-over trial published in BMC Gastroenterology evaluated whether 12 g/day of chicory inulin improves bowel habits, patient-reported outcomes, and gut microbiota...
The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
New guideline recommendations from the ACC/AHA and 9 partner organizations prioritize earlier treatment, refined atherosclerotic cardiovascular disease risk prediction, and broader use of lipid biomarkers...
In a randomized controlled trial of adults with Rome IV irritable bowel syndrome without constipation, investigators found that a Mediterranean-style low-FODMAP diet produced greater symptom improvement,...
Primary care clinicians routinely counsel patients whose eating patterns reflect diverse cultural traditions. This resource offers practical, evidence-based strategies for supporting balanced nutrition...
